QGEN - Qiagen NV logo

QGEN

Qiagen NV

Qiagen N.V. provides molecular testing solutions, offering sample technology consumables and instruments for nucleic acid purification, genotype analysis, and viral testing. Its products serve molecular diagnostics and life sciences sectors worldwide.

βš•οΈ Healthcare NYSE Listed 1996 $ USD
$1,000 invested 10 years ago β†’$1,817today

Score Overview

1 Year
Score
Net Growth-3.66%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth0.50%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score3.7
Net Growth-20.15%
Net Trend20%
Net Income Consistencyβ€”
Rev Growth-6.72%
Rev Trend60%
Revenue Consistencyβ€”
10 Years
Score
Net Growth409.07%
Net Trend40%
Net Income Consistency
Rev Growth56.98%
Rev Trend80%
Revenue Consistency
20 Years
Score6.1
Net Growth480.27%
Net Trend50%
Net Income Consistency
Rev Growth350.94%
Rev Trend85%
Revenue Consistency
30 Years
Score
Net Growth77x
Net Trend63%
Net Income Consistency
Rev Growth38x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth77x
Net Trend63%
Net Income Consistency
Rev Growth38x
Rev Trend90%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Qiagen NV has ranked, year by year

Measure
Fundamentals Window

Showing 20 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • QGEN

2017: 7.6% Β· 2021: 18.8% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 45.01β€”
1 Year2025-09-26
$ 41.299.01%
5 Years2021-09-28
$ 46.80-3.82%
10 Years2016-09-28
$ 24.7781.74%
20 Years2006-09-28
$ 14.38213.04%
30 Years1996-09-27
$ 3.2413x
All Time1996-06-28
$ 1.7126x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 2.10B$ 409M$ 793M
2025$ 2.08B$ 424M$ 1.09B
2024$ 1.97B$ 83M$ 1.15B
2023$ 1.96B$ 341M$ 1.05B
2022$ 2.14B$ 423M$ 1.41B
2021$ 2.25B$ 512M$ 1.06B
2020$ 1.87B$ 359M$ 715M
2019$ 1.52B-$ 41M$ 753M
2018$ 1.50B$ 190M$ 1.41B
2017$ 1.41B$ 40M$ 1.01B
2016$ 1.33B$ 80M$ 532M
2015$ 1.28B$ 130M$ 423M
2014$ 1.34B$ 116M$ 580M
2013$ 1.30B$ 69M$ 382M
2012$ 1.25B$ 129M$ 492M
2011$ 1.16B$ 96M$ 282M
2010$ 1.08B$ 144M$ 934M
2009$ 1.00B$ 137M$ 865M
2008$ 892M$ 89M$ 333M
2007$ 649M$ 50M$ 349M
2006$ 465M$ 70M$ 483M
2005$ 398M$ 62M$ 206M
2004$ 380M$ 48M$ 226M
2003$ 351M$ 42M$ 105M
2002$ 298M$ 23M$ 56M
2001$ 263M$ 34M$ 78M
2000$ 204M$ 21M$ 58M
1999$ 143M$ 13M$ 44M
1998$ 110M$ 13M$ 30M
1997$ 74M$ 8M$ 30M
IPO1996$ 54M$ 5M$ 30M
QGEN - Qiagen NV logo

Qiagen NV fundamental performance

Between 2005 and 2025, revenue grew from $ 398M to $ 2.08B and net income grew from $ 62M to $ 424M. Revenue increased in 17 of those 20 years; net income in 10.

Across Qiagen NV's full reported history, from 1996 to 2025, revenue grew from $ 54M to $ 2.08B and net income grew from $ 5M to $ 424M. Revenue increased in 90% of the years measured; net income in 63%.

Qiagen NV currently holds a 20-year HDB Score of 6.1 out of 10. How the HDB Score is calculated.

Membership

Continue QGEN’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies